By combining IL-6 inhibition with programmed death ligand-1 (PDL-1) targeted therapy in pancreatic adenocarcinoma, improved overall T-cell activation, and anti-tumor response was achieved in a murine model [53,54]. Here, IL6 is linked to neoplasm.